Literature DB >> 23615979

Ependymoma in children: molecular considerations and therapeutic insights.

J-H Kim1, Y Huang, A S Griffin, P Rajappa, J P Greenfield.   

Abstract

A multi-modality approach that encompasses maximal surgical resection in combination with adjuvant therapy is critical for achieving optimal disease control in children with ependymoma. In view of its complex biology and variable response to therapy, ependymoma remains a challenge for clinicians involved in the care of these patients. Meanwhile, translation of molecular findings can characterize unique features of childhood ependymoma and their natural history. Furthermore, understanding the biology of pediatric ependymoma serves as a platform for development of future targeted therapies. In line with these goals, we review the molecular basis of pediatric ependymoma and its prognostic implications, as well as novel therapeutic advances in the management of ependymoma in children.

Entities:  

Mesh:

Year:  2013        PMID: 23615979     DOI: 10.1007/s12094-013-1041-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  57 in total

Review 1.  Cell signaling by receptor tyrosine kinases.

Authors:  J Schlessinger
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

2.  Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics.

Authors:  Piergiorgio Modena; Elena Lualdi; Federica Facchinetti; Joris Veltman; James F Reid; Simone Minardi; Irene Janssen; Felice Giangaspero; Marco Forni; Gaetano Finocchiaro; Lorenzo Genitori; Flavio Giordano; Riccardo Riccardi; Eric F P M Schoenmakers; Maura Massimino; Gabriella Sozzi
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

3.  Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors.

Authors:  S Hing; Y J Lu; B Summersgill; L King-Underwood; J Nicholson; P Grundy; R Grundy; M Gessler; J Shipley; K Pritchard-Jones
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

Review 4.  Telomerase in brain tumors.

Authors:  M L Falchetti; L M Larocca; R Pallini
Journal:  Childs Nerv Syst       Date:  2002-02-23       Impact factor: 1.475

5.  Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.

Authors:  Hendrik Witt; Stephen C Mack; Marina Ryzhova; Sebastian Bender; Martin Sill; Ruth Isserlin; Axel Benner; Thomas Hielscher; Till Milde; Marc Remke; David T W Jones; Paul A Northcott; Livia Garzia; Kelsey C Bertrand; Andrea Wittmann; Yuan Yao; Stephen S Roberts; Luca Massimi; Tim Van Meter; William A Weiss; Nalin Gupta; Wiesia Grajkowska; Boleslaw Lach; Yoon-Jae Cho; Andreas von Deimling; Andreas E Kulozik; Olaf Witt; Gary D Bader; Cynthia E Hawkins; Uri Tabori; Abhijit Guha; James T Rutka; Peter Lichter; Andrey Korshunov; Michael D Taylor; Stefan M Pfister
Journal:  Cancer Cell       Date:  2011-08-16       Impact factor: 31.743

6.  Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis.

Authors:  Matthieu Peyre; Frédéric Commo; Carmela Dantas-Barbosa; Felipe Andreiuolo; Stéphanie Puget; Ludovic Lacroix; Françoise Drusch; Véronique Scott; Pascale Varlet; Audrey Mauguen; Philippe Dessen; Vladimir Lazar; Gilles Vassal; Jacques Grill
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

7.  Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma.

Authors:  Lee Ridley; Ruman Rahman; Marie-Anne Brundler; David Ellison; James Lowe; Keith Robson; Emma Prebble; Inga Luckett; Richard J Gilbertson; Sheila Parkes; Vikki Rand; Beth Coyle; Richard G Grundy
Journal:  Neuro Oncol       Date:  2008-08-13       Impact factor: 12.300

8.  Nucleolin interacts with telomerase.

Authors:  Shilagardi Khurts; Kenkichi Masutomi; Luvsanjav Delgermaa; Kuniaki Arai; Naoki Oishi; Hideki Mizuno; Naoyuki Hayashi; William C Hahn; Seishi Murakami
Journal:  J Biol Chem       Date:  2004-09-14       Impact factor: 5.157

9.  Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma.

Authors:  Stefan Wolfsberger; Ingeborg Fischer; Romana Höftberger; Peter Birner; Irene Slavc; Karin Dieckmann; Thomas Czech; Herbert Budka; Johannes Hainfellner
Journal:  Am J Surg Pathol       Date:  2004-07       Impact factor: 6.394

10.  Generation of an environmental niche for neural stem cell development by the extracellular matrix molecule tenascin C.

Authors:  Emmanuel Garcion; Aida Halilagic; Andreas Faissner; Charles ffrench-Constant
Journal:  Development       Date:  2004-07       Impact factor: 6.868

View more
  5 in total

1.  Solid-cystic cortical ependymoma: a diagnostic dilemma.

Authors:  Moeinadin Safavi; Mohammad Vasei; Zohreh Habibi
Journal:  Childs Nerv Syst       Date:  2021-01-06       Impact factor: 1.475

2.  Cartilage differentiation in ependymoma: histogenetic considerations on a new case.

Authors:  Antonella Coli; Mariangela Novello; Luca Massimi; Massimo Caldarelli; Valentina Ranucci; Libero Lauriola
Journal:  Childs Nerv Syst       Date:  2014-01-22       Impact factor: 1.475

3.  The Survival and Prognostic Factors of Supratentorial Cortical Ependymomas: A Retrospective Cohort Study and Literature-Based Analysis.

Authors:  Qiguang Wang; Jian Cheng; Jiuhong Li; Si Zhang; Wenke Liu; Yan Ju; Xuhui Hui
Journal:  Front Oncol       Date:  2020-08-21       Impact factor: 6.244

4.  A novel technique of serial biopsy in mouse brain tumour models.

Authors:  Sasha Rogers; Hilary Hii; Joel Huang; Mathew Ancliffe; Nick G Gottardo; Peter Dallas; Sharon Lee; Raelene Endersby
Journal:  PLoS One       Date:  2017-04-10       Impact factor: 3.240

5.  Clinical profile, treatment and outcome of pediatric brain tumors in Serbia in a 10-year period: A national referral institution experience.

Authors:  Dragana Stanić; Danica Grujičić; Tatjana Pekmezović; Jelena Bokun; Marija Popović-Vuković; Dragana Janić; Lejla Paripović; Vesna Ilić; Marija Pudrlja Slović; Rosanda Ilić; Savo Raičević; Milan Sarić; Ivana Mišković; Borko Nidžović; Marina Nikitović
Journal:  PLoS One       Date:  2021-10-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.